308 related articles for article (PubMed ID: 21556038)
21. Oncomir MicroRNA-346 Is Upregulated in Colons of Patients With Primary Sclerosing Cholangitis.
Kempinska-Podhorodecka A; Blatkiewicz M; Wunsch E; Krupa L; Gutkowski K; Milkiewicz P; Milkiewicz M
Clin Transl Gastroenterol; 2020 Jan; 11(1):e00112. PubMed ID: 31972611
[TBL] [Abstract][Full Text] [Related]
22. Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.
Wang MH; Mousa OY; Friton JJ; Raffals LE; Leighton JA; Pasha SF; Picco MF; Cushing KC; Monroe K; Nix BD; Newberry RD; Faubion WA
Inflamm Bowel Dis; 2020 Apr; 26(5):774-779. PubMed ID: 31626701
[TBL] [Abstract][Full Text] [Related]
23. Ulcerative colitis complicated by primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome: a case report and literature review.
Zhang X; Lin X; Li X; Guan L; Li Y; Wang N
Front Immunol; 2023; 14():1132072. PubMed ID: 37228618
[TBL] [Abstract][Full Text] [Related]
24. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?
Chapman RW
Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):74-5. PubMed ID: 20134486
[No Abstract] [Full Text] [Related]
25. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
26. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
27. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T; Befeler AS
Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.
Zheng HH; Jiang XL
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):383-90. PubMed ID: 26938805
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea.
Ye BD; Yang SK; Boo SJ; Cho YK; Yang DH; Yoon SM; Kim KJ; Byeon JS; Myung SJ; Yu CS; Yun SC; Kim JH
Inflamm Bowel Dis; 2011 Sep; 17(9):1901-6. PubMed ID: 21830268
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
[TBL] [Abstract][Full Text] [Related]
31. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
32. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis.
Venkatesh PG; Jegadeesan R; Gutierrez NG; Sanaka MR; Navaneethan U
J Crohns Colitis; 2013 Dec; 7(12):968-73. PubMed ID: 23433613
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases.
Florin TH; Pandeya N; Radford-Smith GL
Gut; 2004 Jul; 53(7):973-9. PubMed ID: 15194646
[TBL] [Abstract][Full Text] [Related]
34. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
35. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
36. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Gurbuz AK; Giardiello FM; Bayless TM
Dis Colon Rectum; 1995 Jan; 38(1):37-41. PubMed ID: 7813342
[TBL] [Abstract][Full Text] [Related]
37. Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis.
Navaneethan U; Kochhar G; Venkatesh PG; Bennett AE; Rizk M; Shen B; Kiran RP
J Crohns Colitis; 2013 Dec; 7(12):974-81. PubMed ID: 23523416
[TBL] [Abstract][Full Text] [Related]
38. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
39. Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma.
Aitola P; Mattila J; Matikainen M
Int J Colorectal Dis; 2000 Jun; 15(3):167-71. PubMed ID: 10954188
[TBL] [Abstract][Full Text] [Related]
40. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis.
Brentnall TA; Haggitt RC; Rabinovitch PS; Kimmey MB; Bronner MP; Levine DS; Kowdley KV; Stevens AC; Crispin DA; Emond M; Rubin CE
Gastroenterology; 1996 Feb; 110(2):331-8. PubMed ID: 8566577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
